Compare Aterian Inc (ATER) vs Cytokinetics Inc (CYTK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aterian Inc vs Cytokinetics Inc — how do they compare? Aterian Inc trades at $0.49 (market cap $5.32M), while Cytokinetics Inc trades at $76.62 (market cap $10.63B). The key difference: Cytokinetics Inc is far larger — about 1998.1× Aterian Inc's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Aterian Inc nearer its low. Which is the better fit depends on your goals.
| ATER | CYTK | |
|---|---|---|
Market Cap | $5.32M | $10.63B |
Sector | Consumer Cyclical | Technology |
52-Week High | $1.39 | $87.26 |
52-Week Low | $0.36 | $34.31 |
Enterprise Value | $5.90M | $10.74B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aterian (ATER) trades at $0.48, down 2.72% on the day, with a bearish technical signal. The company reported a net loss of -$18.98M in 2025, though it has beaten EPS estimates in recent quarters. Recent news highlights a pending asset sale that could return $0.85–$1.14 per share to stockholders, subject to a special meeting vote.
The outlook hinges on the asset sale approval, offering potential upside, but ongoing operational losses and negative cash flow pose significant risks. Analyst sentiment is split evenly between Buy and Hold, reflecting uncertainty around the company's restructuring and future profitability.
CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.
The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Aterian Inc
Aterian Inc is a technology-enabled consumer products company. Its product categories include home and kitchen appliances, kitchenware, environmental appliances (dehumidifiers and air conditioners), beauty-related products, and consumer electronics. It has various owned and operated brands include Vremi, Healing Solutions, Xtava, TRUWEO, Spiralize, Pohl+Schmitt, and RIF6. The company generates revenue through the online sales of various consumer products that are sold online.
Read more on ATER →About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →
